Boston · Seed–Series B · 47 people tracked
Also known as LONGWOOD MANAGEMENT LLC
Find your way into Longwood Fund
2,551 people in our graph share verified history with the Longwood Fund team — schools, employers, funds. One of them is your warm intro.
Investment thesis
Longwood Fund focuses on creating and investing in novel healthcare and biotech companies that develop important treatments for patients. The firm acts as company co-founders and value-add investors, partnering with entrepreneurs, scientists, and academic innovators to turn groundbreaking discoveries into companies. It leverages its own company creation and operating experience to build businesses that both benefit patients and generate significant investor value. Its partners have founded over 20 biotech companies, which have launched roughly 25 drugs.
Source: firm website, verified Sep 15, 2026.
Team · 47 people
from the firm's website & curated & public directories
Founder mafia
5 people who came through Longwood Fund went on to found or lead other companies.
What they invest in
from 47 of 74 portfolio companiesBiotech ×39Healthtech ×27Medical Devices ×18AI & Machine Learning ×5Deep Tech ×5Digital Health ×4Consumer ×2Direct to Consumer ×1
HQs:United States×33Canada×1
Who they back
founder profiles across 16 portfolio companiesFounding team size:solo founder×82 founders×43 founders×14+ founders×3
Where their founders studiedfrom 18 founders with education data
KU Leuven ×3Imperial College London ×2UCL ×2Université Louis Pasteur (Strasbourg I) ×2
What their founders studiedfrom 18 founders with field-of-study data
Life Sciences ×11Medicine ×4Chemistry ×2Engineering ×2
Where their founders worked beforefrom 20 founders with career history
Galapagos ×9Aligos Therapeutics ×3Johnson & Johnson ×3Janssen Europe, Middle East & Africa (EMEA) ×2Longwoodfund ×2Maverick Therapeutics ×2MPM BioImpact ×2Potenza Therapeutics ×2
Investments · 74 tracked
founders shown can be your intro pathBy year:2026 · 22025 · 22024 · 52023 · 22022 · 42021 · 52020 · 12019 · 22018 · 12017 · 12015 · 12014 · 127 dated
Camp4 Therapeutics develops antisense oligonucleotides targeting regulatory RNAs to increase gene expression and restore healthy protein levels for genetic diseases, with an initial focus on treating SYNGAP1-related developmental and epileptic encephalopathy.
BiotechCambridge, US
Richard Young(Director (Class II))JOSH MANDEL-BREHM(Executive Officer, Director)inJosh Mandel-Brehm(Chief Executive Officer and Director (Class III))in
BoardMICHAEL HIGGINS(Director)JORGE CONDE(Director)inAMIR NASHAT(Director)in
Board seatShaan C. Gandhi· per SEC Form D · filed Oct 2021
Co-investors5AM VenturesAndreessen HorowitzPolaris Partners
Pyxis Oncology is a clinical-stage biotech company developing antibody-drug conjugates for solid tumors, with its lead candidate targeting a fibronectin variant found in tumor tissue but not healthy tissue.
HealthtechBoston, US
Thomas Civik(Interim Chief Executive Officer, Director)
BoardGeeta Vemuri(Director)inJak Knowles(Director)John Flavin(Director)
Board seatDavid SteinbergChristoph Westphal· per SEC Form D
Co-investorsAgent CapitalRA CapitalRTW Investments L.P.
Bicycle Therapeutics develops precision-guided therapeutics based on its proprietary bicyclic peptide (Bicycle) technology, designed to penetrate deep into tissues and target intractable solid tumor cancers.
BiotechHealthtechCambridge
GREGORY WINTER(Director)inKEVIN LEE(Executive Officer, Director)inNIGEL CROCKETT(Executive Officer)inNICHOLAS KEEN(Executive Officer)SANTIAGO ARROYO(Executive Officer)inMICHAEL HANNAY(Executive Officer)
Co-investorsAhren Innovation CapitalAstellas Venture Management LLCCambridge Innovation CapitalSR One Capital ManagementSV Health InvestorsVertex Ventures HC
GRAIL develops the Galleri blood test for multi-cancer early detection using next-generation sequencing and machine learning to screen for multiple deadly cancer types before symptoms appear.
AI & Machine LearningBiotechHealthtechMedical DevicesMenlo Park, US
Jeffrey T. Huber(Director)Joshua Ofman, MD, MSHS(Chief Executive Officer)inAaron Freidin(Executive Officer)inJosh Ofman(Executive Officer)inRobert Ragusa(Executive Officer, Director)Jennifer Cook(Executive Officer, Director)in
Co-investorsAmino CapitalARCH Venture PartnersBezos ExpeditionsBluebird VenturesDecheng CapitalDentsu Ventures+8 more
-2.png)
PTC is a global pharmaceutical company focused on the discovery, development, and commercialization of medicines for patients with rare diseases who have few or no treatment options.
BiotechHealthtechSouth Plainfield, US
Stuart W. Peltz(Executive Officer, Director)Allan S. Jacobson(Director)inAllan Jacobson(Director)inMark E. Boulding(Executive Officer)inChristine Utter(Executive Officer)inMarcio Souza(Executive Officer)in
Co-investorsBay City Capital
Verastem Oncology is a biopharmaceutical company that discovers and develops drugs to treat cancer patients.
BiotechMedical DevicesNeedham, US
Robert WeinbergRICHARD ALDRICH(Director)AMY C. CAVERS(Executive Officer)inCATHY CAREW(Executive Officer)inJONATHAN PACHTER(Executive Officer)inROB GAGNON(Executive Officer)in
Co-investorsBessemer Venture PartnersCardinal PartnersForesite CapitalLightstone VenturesOberland CapitalOrbiMed
Engrail Therapeutics is a clinical-stage pharmaceutical company developing precision-targeted therapeutics for neupropsychiatric and neurodevelopmental disorders.
BiotechDigital HealthMedical DevicesSan Diego, US
Stephen(Co-founder, EVP Research & Development and Chief Development Officer)Paul Cayer(Chief Financial Officer)inVikram(President and Chief Executive Officer)Kimberly(Chief Scientific Officer)Quentin(Chief Technical Officer)
Co-investorsForesite CapitalNorwest Venture PartnersRiverVest Venture PartnersYsios Capitalabrdn plcEight Roads Ventures+4 more
Longwood Fund is a biotech-focused investment firm that both creates and invests in early-stage biotechnology companies developing therapies for unmet medical needs.
BiotechDeep TechMedical DevicesMental Health
Co-investorsDC Investment Partners
Newleos is a biopharmaceutical company developing therapies for neuropsychiatric and neurodevelopmental disorders.
Biotech
Federico Bolognani(Co-founder, Chief Medical Officer)Christoph Westphal(Co-founder, Director)
Photys Therapeutics develops bifunctional small-molecule medicines that use induced proximity to recruit kinases and drive targeted protein phosphorylation, aiming to modulate and repair disease-driving proteins.
BiotechHealthtechLongevityWaltham, US
Amit Choudhary(Scientific Founder)David Steinberg(Chairman & Founding CEO)inEdward Holson(Co-founder & CSO)inLizzie Ngo(Co-founder)inBrian Fenton(President & CEO)in
Co-investorsMPM BioImpact8VCMRL Ventures FundOno Venture Investment, Inc.
Sitryx is a biotechnology company, founded in 2018, developing therapeutics with a focus on immunometabolism.
BiotechDeep TechHealthtech
Co-investorsOxford Science EnterprisesSofinnova PartnersSV Health Investors
Anuncia Medical develops medical technology focused on cerebrospinal fluid (CSF) science and clinical strategy to advance hydrocephalus treatment.
BiotechHealthtechMedical DevicesScottsdale, US
Darryl Baker(Executive Officer)Elsa Abruzzo(Executive Officer, Director)in
BoardEdgar D Janotta(Director)Stanton Rowe(Director)Stephen Oesterle(Director)
Board seatDavid Donabedian· per SEC Form D · $16.4M raise · filed Nov 2025
Co-investorsXcellerant Ventures
HealthtechLexington, US
Barbara S. Fox(Executive Officer, Director)Eileen F. Bostwick(Executive Officer)David C. Dlesk(Executive Officer)David Poorvin(Executive Officer, Director)
BoardJonathan Fleming(Director)
Board seatDavid Donabedian· per SEC Form D · $5M raise · filed Jul 2015
Co-investorsBoston Harbor AngelsKeiretsu Forum
The page presents Pinco Casino, an online gambling platform offering slots, live casino, table games, and sports betting with a Turkish-language interface.
ConsumerGamingHealthtechBoston, US
Robert Kotin(Executive Officer, Director)Chen Schor(Director)Robert Hadfield(Executive Officer)John Lawrence(Executive Officer)
BoardGeeta Vemuri(Director)inDerek Yoon(Director)in
Board seatDavid Steinberg· per SEC Form D
Co-investorsAstellas Venture Management LLCDC Investment PartnersSolasta VenturesUTokyo Innovation Platform Co. Ltd.Agent Capital
Colorescience is a professional skincare brand that develops mineral-based sun protection (SPF), skincare, and color correction products, originally created for post-procedure skin and marketed for all ages and skin types.
ConsumerDirect to ConsumerHealthtechWellness & FitnessCarlsbad, US
Stephen Loomis(Executive Officer)Mary Fisher(Executive Officer, Director)inTheodore Ebel(Executive Officer)Josie Juncal-Schwarz(Executive Officer)
BoardM Bolyard(Director)Brian Dovey(Director)in
Board seatRichard Aldrich· per SEC Form D
Co-investors1315 CapitalAisling CapitalDomain AssociatesHealthCare Ventures, LLCRoundTable Healthcare PartnersSplit Rock Partners
Immunitas discovers and develops therapeutic antibodies for cancer and autoimmune diseases, with its lead program targeting CD161 for solid tumors and hematological malignancies.
BiotechDigital HealthMedical DevicesWaltham, US
Amanda Wagner(Executive Officer)Dan Matloff(Executive Officer)Jiaping Gu(Director)Jeffrey Goldberg(Executive Officer, Director)
BoardLaura Brass(Director)inKai Wucherpfennig(Director)
Board seatChristoph Westphal· per SEC Form D
Co-investorsAgent CapitalDC Investment PartnersMedical Excellence CapitalNovartis Venture FundOno Venture Investment, Inc.Solasta Ventures+2 more
BiotechBoston, US
David Donabedian(Executive Officer, Director)inRobert Hadfield(Executive Officer)inJohn McCabe(Executive Officer)in
BoardMing Cheah(Director)inRaymond Camahort(Director)
Board seatChristoph Westphal· per SEC Form D
Co-investorsDCVC (Data Collective)DCVC BioNovo Holdings
A company focused on developing clinical treatments aimed at improving patient outcomes.
BiotechHealthtechMedical DevicesBoston, US
David Southwell(Executive Officer, Director)inRobert Crane(Executive Officer)
BoardSteve Kraus(Director)inCampbell Murray(Director)inHannes Smarason(Director)in
Board seatChristoph WestphalLea Hachigian· per SEC Form D
Co-investorsAstellas Venture Management LLCBessemer Venture PartnersRA Capital6 Dimensions CapitalLongwood Special SituationsPitango
An R&D-driven biopharmaceutical company that uses AI to develop breakthrough medicines and vaccines focused on immune system disorders across five therapeutic areas.
AI & Machine LearningBiotechMedical DevicesCambridge, US
Ivana Magovcevic-Liebisch(Executive Officer, Director)Christopher Verni(Executive Officer)inMary Thistle(Director)Evan Thackaberry(Executive Officer)Suzanne Bruhn(Director)Gerhard Koenig(Director)
Board seatShaan C. Gandhi· per SEC Form D · $75M raise · filed Aug 2022
Co-investorsAtlas VentureLightstone VenturesVida VenturesHatteras Venture Partners
Werewolf Therapeutics is a biotechnology company developing immunotherapy treatments for cancer.
BiotechHealthtechMedical DevicesWatertown, US
Daniel J. Hicklin(Founder, President, Chief Executive Officer, and Board member)Luke Evnin(Co-founder, Board member (Chairman))inDaniel Hicklin(Executive Officer, Director)David Cordo(Executive Officer)Alon Lazarus(Director)
Board seatChristoph Westphal· per SEC Form D
Co-investorsDC Investment PartnersK2 HealthVenturesMPM BioImpactRA CapitalTaiho Ventures, LLC
Co-investorsNeva Sgr.Sofinnova PartnersXGEN Venture
Neomorph develops a molecular glue discovery platform to identify small-molecule medicines that degrade disease-causing proteins through targeted protein degradation.
AI & Machine LearningBiotechDeep TechSan Diego, US
Co-investorsDeerfield Management Company
HealthtechBoulder, US
Jason Myers(Executive Officer, Director)Christian LaPointe(Executive Officer)
BoardKyle Lefkoff(Director)inPaul Manning(Director)in
Co-investorsCrawley VenturesBoulder VenturesPBM Capital
Avenzo Therapeutics is a clinical-stage biopharmaceutical company developing therapeutic treatments.
Biotech
Athena Countouriotis(Co-Founder, Chief Executive Officer)
Co-investorsDelos CapitalForesite CapitalINCE CapitalNew Enterprise Associates (NEA)OrbiMedQuan Capital+3 more
Restaurant tech company; $100M exit.
Co-investorsAnalog VenturesBranded Strategic HospitalityFour Acres CapitalGV (Google Ventures)Rally Ventures Management, LlcSupernode Ventures+2 more
BridgeBio develops treatments for genetic conditions and cancers using a decentralized hub-and-spoke model, where autonomous teams focus on specific diseases or drug candidates while a central hub provides clinical, regulatory, and commercial support.
BiotechHealthtech
Co-investorsAisling CapitalAmzak HealthEcoR1 CapitalFrazier Life SciencesHEALTHCARE ROYALTY PARTNERSSequoia Capital
Calithera Biosciences was a clinical-stage biopharmaceutical company developing small-molecule oncology drugs targeting tumor metabolism, including the glutaminase inhibitor telaglenastat.
BiotechSouth San Francisco, US
Susan M. Molineaux(Executive Officer, Director)inWilliam Waddill(Executive Officer)in
BoardJean M. George(Director)Deepa Pakianathan(Director)inRalph E. Christoffersen(Director)Jonathan Drachman(Director)
Co-investorsVenture Capital Investment Management
HealthtechEmeryville, US
Bill Malecki(Executive Officer)Daniel Burnett(Director)Ulric Cote(Executive Officer, Director)
BoardDr. Jason Hong(Director)Anthony Natale(Director)inCarter Mayer(Director)
Co-investorsAPERTURE Venture PartnersGreen Park & Golf VenturesScientific Health DevelopmentThird Point VenturesVHM
Coultreon is a drug discovery and development company that advances small and large molecule therapeutic programmes across various disease areas, combining disease biology expertise with technology platforms.
AI & Machine LearningBiotech
Pierre Raboisson(Chief Executive Officer Chief Scientific Officer Co-founder)inMarie De Vulder(Chief Legal Officer Co-founder)inGuy Peeters(Chief Financial Officer Co-founder)inJohn-Paul Gallivan(Head of Development Co-founder)inFabrice Kolb(Head of Immunology Co-founder)inPieter Peeters(Operating & Technology Officer Co-founder)in
Co-investorsSofinnova VenturesBAM ElevateFinchley Healthcare VenturesForbionLuma GroupNovo Holdings+1 more
Crystalys Therapeutics is a clinical-stage biopharmaceutical company developing targeted therapies for gout, a chronic metabolic disease caused by elevated uric acid.
BiotechHealthtechMedical DevicesSan Diego, US
James Mackay(President & Chief Executive Officer)inNihar Bhakta(Chief Medical Officer)inAshwin Ram(Chief Operating Officer)inDeAnne Reid(Chief Administrative Officer)in
Co-investorsCatalys PacificNovo HoldingsAN Venture PartnersFrazier Life SciencesLightstone Ventures
DEM BioPharma is a biotechnology company developing cancer therapies by targeting the immune system, drawing on genetic and immuno-oncology research.
BiotechHealthtechCambridge, US
Nenad Grmusa(Chief Executive Officer)inJohn McCabe(Chief Financial and Operating Officer)in
Co-investorsAlta PartnersAstellas Venture Management LLCDC Investment PartnersPfizer Venture InvestmentsUTokyo Innovation Platform Co. Ltd.Insight Partners+1 more
Evommune develops therapies targeting the underlying sources of chronic inflammatory diseases, aiming to provide underserved patient populations with more than symptomatic relief.
BiotechHealthtechPalo Alto, US
Luis Pena(Executive Officer, Director)inJanice Drew(Executive Officer)David Cohen(Director)Gregory Moss(Executive Officer)Eugene Bauer(Executive Officer, Director)Francois Beaubien(Director)
Co-investorsAndera PartnersAvego BioScience CapitalB Capital GroupB4 CapitalBeiersdorf Innovation FundFemHealth Ventures+3 more
.jpeg){kind=logo}
Flex Pharma provides accessible generic vasodilator medications, including PDE5 inhibitors, to U.S. patients at lower costs than brand-name alternatives.
BiotechDigital HealthHealthtechMedical Devices
Dr. Rod MacKinnon(Founder)
Co-investorsBessemer Venture PartnersEcoR1 CapitalLightstone Ventures
IlluminOss Medical makes a light-curable, patient-conforming intramedullary implant for minimally invasive fracture repair.
Co-investorsExcel Venture ManagementSlater Technology Fund
KalVista Pharmaceuticals is a global biopharmaceutical company that develops oral therapies for rare diseases, starting with hereditary angioedema (HAE).
BiotechHealthtech
Co-investorsFrazier Life SciencesRA Capital
Khartis is a drug discovery company developing oral therapies for patients with immune-mediated and chronic diseases.
BiotechMedical Devices
Co-investorsForesite CapitalNextech InvestAlexandriaLilly Asia Ventures
Lassen Therapeutics is a biotechnology company developing therapeutics targeting IL-11, with a pipeline focused on immune and fibrotic diseases.
Biotech
David King(Co-Founder & CSO)inMaria Fardis(CEO)inCadmus C. Rich(Chief Medical Officer)inElaine Stracker(General Counsel)in
Co-investorsAlta PartnersCatalio Capital Management, LPDC Investment PartnersLongitude CapitalBiotechnology Value FundCatalio Capital Management+2 more
Mediartx develops novel therapies for patients with fibrotic diseases.
BiotechMedical DevicesBoston, US
Rahul Ballal, PhD(CEO)Paul Yaworsky, PhD(CSO)inRahul Ballal(Executive Officer, Director)inBrian Hubbard(Director)Stacey Brenner(Executive Officer)David de Graaf(Director)
Co-investorsAgent CapitalMission BiocapitalNovartis Venture FundOno Venture Investment, Inc.Pfizer Venture InvestmentsShangBay Capital LLC+2 more
Progentos develops small-molecule therapeutics to stimulate myelin regeneration in multiple sclerosis patients by activating oligodendrocyte progenitor cells.
BiotechDeep TechMedical DevicesWatertown, US
Dmitrij Hristodorov(Director)inChristopher Loose(Executive Officer, Director)Sanjay Magavi(Executive Officer)Marc-Olivier Turgeon(Director)in
BoardAleks Radovic-Moreno(Director)inDan Janney(Director)
Co-investorsAlta PartnersMission BiocapitalService Provider CapitalDolby Family VenturesForbion
Pulmocide is a biopharmaceutical company developing inhaled therapies for difficult-to-treat respiratory diseases, currently focused on respiratory fungal infections such as pulmonary aspergillosis.
BiotechHealthtech
Pete Strong(Co-founder)Garth Rapeport(Co-founder)inKazuhiro Ito(Co-founder)inJohn Murray(Co-founder)inDavid Mantusin
Co-investorsAdjuvant CapitalF-Prime CapitalJeito CapitalSR One Capital ManagementSV Health InvestorsVivo Capital+2 more
Rectify Pharma is a biotechnology company developing therapies, with a pipeline that has included work in liver and metabolic disease areas.
BiotechDeep Tech
Rajesh Devraj(President and Chief Executive Officer)inRobert Hughes(Chief Scientific Officer)inPol Boudes(Chief Medical Officer)
Co-investorsAtlas VentureDC Investment Partners
Sidewinder Therapeutics is a biotechnology company focused on oncology drug discovery and development, working on next-generation cancer treatments.
BiotechHealthtechMedical DevicesSan Diego, US
Eric Murphy(Chief Executive Officer, Co-Founder, & Director)in
Co-investorsAstellas Venture Management LLCDCVC (Data Collective)DCVC BioFrazier Life SciencesNovartis Venture FundOrbiMed+1 more
Solu Therapeutics is a clinical-stage biotech developing a class of antibody therapeutics that link bifunctional small molecules to proprietary effector antibodies (its CyTAC and TicTAC platforms) to reach cell surface targets like GPCRs and ion channels.
BiotechHealthtech
Phil Vickers(CEO / Leadership)inMichael Boretti(Leadership)inBrandon Turunen(Leadership)inSergio Santillana(Leadership)Enda Moran(Leadership)inKelly Honohan(Leadership)in
Co-investorsAstellas Venture Management LLCPappas Capital
Pyxis Oncology develops antibody-drug conjugates and immunotherapies targeting difficult-to-treat cancers to improve patient outcomes.
BiotechDigital HealthHealthtechMedical Devices
Co-investorsPfizer Venture InvestmentsAgent Capital
Xaira develops AI and machine learning tools for drug discovery and protein design, serving pharmaceutical and biotech companies.
AI & Machine LearningBiotechMedical DevicesSouth San Francisco, US
Hetu Kamisetty(Founder)Marc Tessier-Lavigne(Founder)inDr. Ci Chu(Chief Discovery Officer)Dr. Bo Wang(Chief AI Scientist)Dr. Ian McCaffery(SVP, Translational Science and Early Clinical Development)
Co-investorsARCH Venture PartnersBreyer CapitalF-Prime CapitalForesite CapitalMenlo VenturesNew Enterprise Associates (NEA)+1 more
XyloCor Therapeutics develops gene therapies for advanced coronary artery disease and cardiac damage.
BiotechHealthtechMedical DevicesMalvern, US
Ronald Crystal(Co-founder)Todd Rosengart(Co-founder)John Tucker(President and Chief Executive Officer)Albert Gianchetti(Executive Officer, Director)
BoardGlenn Batchelder(Director)inJames Cohen(Director)
Co-investorsLumira VenturesFountain Healthcare PartnersJeito CapitalSofinnova Ventures
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Alcyone TherapeuticsAxial BiotherapeuticsNeela TherapeuticsRenoviaAavantgardeAavantgardebioAlnaraArcherBe BioBE BiopharmaBebiopharmaCalitheraCarbonCrystalysDemInteriusInterius BioTherapeuticsKalVista PharmaceuticalsMediarMillendoMillendo TherapeuticsMitobridgeRectifyRectify PharmaceuticalsSidewindervisit www.interiusbio.comWeaverWerewolf
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.
Exits · 9
6 IPOs · 3 acquisitions · showing 8Camp4 Therapeutics CorpNASDAQ: CAMPPyxis OncologyNASDAQ: PYXSBicycleNASDAQ: BCYCGRAILNASDAQ: GRALPtcbioNASDAQ: PTCTVerastemNASDAQ: VSTMAlnaraacq. by Eli Lilly and CompanyMillendo Therapeuticsacq. by Tempest Therapeutics
Portfolio news
latest coverage across their companies
Pyxis Oncology · scanx.trade · Aug 20, 2026
Khartis Therapeutics · allsci.com · Aug 14, 2026
Evommune · stocktitan.net · Aug 6, 2026
Sidewinder Therapeutics · techcrunch.com · Jul 30, 2026
GRAIL · simplywall.st · Jul 17, 2026
Xaira Therapeutics · thenextweb.com · Jul 15, 2026
Avenzo · geekwire.com · Jul 13, 2026
IPO stake values · per SEC filings · 2
Value of this firm's stake in each portfolio company at its IPO price, from the prospectus principal-stockholder table.
| Company | Owned | IPO price | At IPO | Stake value |
|---|---|---|---|---|
| Pyxis Oncology | 3.7% | $16.00 | Oct 2021 | $19.4M |
| Bicycle | 3.9% | $14.00 | May 2019 | $9.8M |
Source: SEC S-1 / 424B prospectus filings. Stake value = shares beneficially owned × the initial public offering price, as disclosed — a market value at IPO, not a return multiple (the firm's original cost is not disclosed).
Frequently asked questions
- How many investments has Longwood Fund made?
- Longwood Fund has 74 tracked investments, 9 of which have exited, including 4 dated in the last 24 months.
- What stage does Longwood Fund invest at?
- Longwood Fund invests at the Seed, Series A, Series B stages.
- What sectors does Longwood Fund focus on?
- Longwood Fund focuses on Biotech, Deep Tech, Healthtech, Medical Devices.
- Where is Longwood Fund located?
- Longwood Fund is headquartered in Boston, US.
- Does Longwood Fund lead rounds?
- Longwood Fund typically participates in rounds rather than leading them.
- Who does Longwood Fund co-invest with?
- Longwood Fund most often shares deals with DC Investment Partners, Frazier Life Sciences, Alta Partners, among 92 tracked co-investors.
Images
Co-investors · 15
Agent Capital is a healthcare venture capital firm that invests in novel, differentiated therapeutics and treatments addressing unmet patient needs across all stages of development.
Alta Partners is a venture capital firm focused on the healthcare and life sciences sector, backing entrepreneurs building companies across biotechnology, therapeutics, and healthcare innovation.
Atlas Venture is a life sciences venture capital firm with three decades of experience investing in and building biotech and medical innovation companies, including startups launched from its own incubator.
OrbiMed is a global healthcare-focused investment firm providing financing and operational support to companies across biopharmaceuticals, medical devices, digital health, diagnostics, and healthcare services.
Sofinnova Partners is a life sciences venture capital firm investing across the value chain from seed to later stage, with a focus on healthcare and sustainability. It backs companies in biopharma, medtech, digital medicine, agriculture and industrial processes.
Forbion is a global venture capital firm focused on advancing biotech innovations and sustainable solutions aimed at improving human and planetary health.
5AM Ventures is a life science venture capital firm founded in 2002 that invests primarily in private therapeutic companies, with a focus on biopharmaceuticals, drug delivery technologies, and life science instruments.
MPM BioImpact combines 30+ years of biotech venture capital expertise with impact investing and public market experience, managing early-stage venture funds, private/public impact funds, and a public equities fund focused on transforming patient outcomes.
Aisling Capital is an investment firm focused on companies developing and commercializing innovative healthcare products, services, and technologies.
Andreessen Horowitz (a16z) is a venture capital firm founded in 2009 by Marc Andreessen and Ben Horowitz, known for pioneering the platform model with a large team of operators supporting founders across stages.
Kleiner Perkins is a venture capital firm that backs founders across technology and life sciences, from early stage through growth.
B Capital is a global investment firm backing early to late-stage technology innovators across technology, healthcare, and energy & resilience sectors.
▶3 more co-investors
Longitude CapitalWestlake Village BioPartnersDe Novo Ventures
Firms observed investing alongside Longwood Fund, from public investor directories. Shared companies are the overlap with Longwood Fund's recorded portfolio.
Similar investors
ACT Venture Capital is an independent Irish venture capital firm that invests €1 million to €15 million in growth-stage private companies, with capacity for larger commitments through syndicated rounds.
Amadeus Capital Partners is a technology investment firm that backs founders building complex, science-led and deep tech businesses, supporting them over the long term as they scale internationally.
B Capital is a global investment firm backing early to late-stage technology innovators across technology, healthcare, and energy & resilience sectors.
Capricorn Partners is a Belgium-based, partner-owned independent management company for alternative investment funds, investing in innovative companies across digital, health and clean technologies with an ESG focus.
DCVC (Data Collective) is a deep tech venture capital firm that backs entrepreneurs using computational approaches to solve large-scale real-world problems across many industries.